Furosemide-Induced Hearing Loss
Introduction to Furosemide-Induced Hearing Loss
- The American Journal of Respiratory and Critical Care Medicine recommends that furosemide administration be stopped if tinnitus or hearing changes occur, and alternative medications be used if possible, to minimize the risk of permanent hearing loss 1
Risk Factors for Furosemide-Induced Hearing Loss
- Patients with severe renal impairment, hypoproteinemia, dehydration, advanced age, and pre-existing hearing problems are at higher risk of furosemide-induced hearing loss, and should be monitored closely 1
Administration Factors
- Rapid intravenous injection of furosemide is associated with the highest risk of hearing loss, and should be avoided, with infusion rates not exceeding 4 mg/minute for adults 1
Concomitant Medications
- The use of furosemide with aminoglycoside antibiotics, ethacrynic acid, cisplatin, and other ototoxic drugs increases the risk of hearing loss, and should be avoided except in life-threatening situations 1
Monitoring and Prevention
- Baseline audiometry and regular audiometric testing during prolonged therapy can help identify early symptoms of ototoxicity, and should be performed in high-risk patients 1
- The use of the lowest effective dose, and consideration of dose reduction in elderly patients or those with renal impairment, can also help minimize the risk of furosemide-induced hearing loss 1
Assessment and Follow-up
- If ototoxicity is suspected, audiometric evaluation should be performed, and other causes of hearing loss should be ruled out, with monitoring for recovery and consideration of permanent hearing aids if hearing loss persists 1